Pan-Chyr Yang
楊泮池
MD, PhD
Distinguished Professor, College of Medicine; Former President, NTU医学院特聘教授；前台大校长
👥Biography 个人简介
Prof. Pan-Chyr Yang is a founding figure of molecular lung cancer research in Asia. As former president of National Taiwan University and pioneering molecular epidemiologist, he established the high prevalence of EGFR mutations in Asian never-smokers, providing the scientific basis for EGFR-targeted therapy across the Asia-Pacific.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
EGFR Mutations in Asian Never-Smokers
Among the first to characterize the high prevalence of EGFR-activating mutations in Asian never-smoking lung adenocarcinoma patients, directly motivating EGFR TKI development for Asian populations.
Molecular Epidemiology
Established Taiwan's prospective lung cancer molecular profiling cohorts, linking EGFR, KRAS, and ALK alterations to clinical outcomes and creating a globally referenced Asian dataset.
Biomarker Discovery
Discovered novel microRNA and protein biomarkers for early lung cancer detection, with translational work advancing non-invasive diagnostic approaches for Asian populations.
Representative Works 代表性著作
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
Science (2004)
Co-authored landmark Science paper identifying activating EGFR mutations as the molecular basis for gefitinib sensitivity, one of the most cited papers in cancer biology.
MicroRNA expression profiles discriminate early stage lung adenocarcinomas from normal tissue
Nature Medicine (2007)
Identified diagnostic microRNA signatures for early-stage lung adenocarcinoma, opening a new avenue for minimally invasive biomarker-based screening strategies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 楊泮池 的研究动态
Follow Pan-Chyr Yang's research updates
留下邮箱，当我们发布与 Pan-Chyr Yang（National Taiwan University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment